

26TH PRINCETON CONFERENCE

Hotel ZaZa – Houston Museum District

Organizer: James C. Grotta, MD



FRIDAY, MARCH 28, 2008

8:00 AM – 9:30 AM

- **NEUROVASCULAR UNIT** - Moderators: Gary Rosenberg and Eng Lo

1. Eng Lo: Intro and endo-neuron signaling in NVU
2. Maiken Nedergaard: Astro-neuron and astro-endo signaling in NVU
3. Mark Fisher: Pericyte signaling
4. Jin-Moo Lee: Diseases of the NVU: Cerebral Amyloid Angiopathy
5. Gary Rosenberg: Clinical diseases of the NVU (stroke and dementia)

Moderated Discussion: Paula Dore-Duffy, Greg del Zoppo, Tom Jacobs.

10:00 AM – 11:30 AM

- **IMAGING AND BIOMARKERS** - Moderators: Roger Simon and Steve Warach

1. Max Wintermark: MR and CT monitoring of Reperfusion and Penumbra Salvage
2. Steven Cramer: Use of imaging in restorative stroke trials
3. Michael Moseley: MR in Molecular Imaging: Impact on Stroke Research
4. Mary Stenzel-Poore: Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia
5. Edward Neuwelt: The Blood Brain Barrier and Imaging of Cell Migration in Ischemic Brain

Moderated Discussion

11:30 AM – 1:00 PM LUNCH

1:00 PM – 2:30 PM

- **VASCULAR COGNITIVE IMPAIRMENT** - Moderators: Constantino Iadecola and Sandra Black

1. Costantino Iadecola: Threats to the mind: Aging, amyloid and hypertension
2. Mark Goldberg: Molecular mechanisms of white matter disease
3. Martin Dichgans: CADASIL: bench to bedside
4. Sandra Black: Imaging white matter disease: challenges and opportunities
5. Lenore Launer : Co-existing Alzheimer's and Cerebrovascular Pathology: Coincidence or Synergy?

Moderated Discussion: V. Hachinski and B. Zlokovic (15 min)

3:00 PM – 4:30 PM

• **PREVENTION 1 – GENETICS - Moderators: Karen Furie and Katrina Gwinn**

1. Eric Boerwinkle: Deciphering the Genetics of Complex Diseases: Lessons Learned

What can we learn from other complex diseases such as diabetes, cardiac disorders, rheumatoid arthritis? How do those lessons NOT apply?

2. Dong Kim: Familial Studies of Cerebral Aneurysms

Traditional familial approach to cerebral aneurysms. What are the phenotypes of interest? What are the strengths and weaknesses of this approach?

3. James Meschia: Whole Genome Approaches in Ischemic Stroke

Genetic databases, what have we learned from gene discovery in other complex diseases such as diabetes, both scientifically and in terms of how to build consortia and bring gene discovery to fruition in a complex field?

4. Jonathan Rosand: Incorporating Genetic Data into Therapeutic Decision-Making

Genotype stroke risk in sickle cell children, genetic predictors of warfarin response as models of genetic based prevention strategies.

5. Marco Ramoni: Bayesian approaches to stroke genetics.

Moderated Discussion

5:00 PM – 6:30 PM

• **PREVENTION 2 - HIGH RISK POPULATIONS - Moderators: George Howard and Ralph Sacco**

1. Phil Wolf: Traditional Risk Factor Prediction Scores

2. Dawn Kleindorfer: Sociodemographic groups at high risk for stroke: Race and Ethnicity

3. Steve Pavlakis: Stroke Risk Prediction among Children and Young Adults

4. Bruce Coull: Novel Risk Predictors - Biomarkers and Subclinical Measurements

5. Phil Gorelick: Challenges for Designing Primary Prevention Trials

Moderated Discussion

7:30 PM – 9:30 PM

DINNER & KEYNOTE LECTURE

★ **Introductory Speaker: JAMES T. WILLERSON, MD**

*President & Alkek-Williams Distinguished Professor and Edward Randall III Chair in Internal Medicine
University of Texas Health Science Center - Houston, TX*

President-Elect & Medical Director, Texas Heart Institute

“Cerebrovascular Research at UT Medical School and Stem Cell Therapy for Heart Failure”

★ **Keynote Speaker: CHENG CHI LEE, PHD**

Professor, Biochemistry and Molecular Biology - University of Texas Medical School - Houston, TX

“Suspended Animation in Non-hibernating Mammals”

SATURDAY, MARCH 29, 2008

7:30 AM – 9:00 AM

- **BRAIN HEMORRHAGE** - Moderators: Lewis Morgenstern and Jaroslaw Aronowski

1. **John H. Zhang:** The Central Role of Early Brain Injury after Subarachnoid Hemorrhage.
2. **Guohua Xi:** Thrombin in brain recovery after intracerebral hemorrhage
3. **Magdy Selim:** A New Hope for ICH: Deferoxamine Mesylate. From Bench to Clinical Trials.
4. **Jaroslaw Aronowski:** Hematoma resolution as therapeutic target; role of microglia/macrophages.
5. **William Young:** Determinants of brain AVM hemorrhage and their implication for therapeutic development

Moderated Discussion: Steve Greenberg and Marc DelBigio

9:30 AM – 11:00 AM

- **REPERFUSION** - Moderators: Joseph Broderick, Jeffrey Saver

1. **Clark Haley:** New fibrinolytic agents
2. **Art Pancioli :** Combination Pharmacotherapy for Achievement and Maintenance of Vascular Patency
3. **Joseph Broderick:** Endovascular Therapies
4. **Andrei Alexandrov:** Ultrasound Enhancement of Fibrinolysis
5. **Steve Warach:** Lessons from Recent Studies on Trial Design and Patient Selection via Imaging

Moderated Discussion

11:30 AM – 1:00 PM

- **NEUROPROTECTION** - Moderators: Myron Ginsberg, Pat Lyden

1. **Myron Ginsberg:** The current status of the field of ischemic neuroprotection: a brief critical overview.
2. **Sean Savitz:** The cosmic implications (of lack thereof) of NXY-059's clinical-trial failure?
Does the pharmaceutical industry select the most promising agents for development? Did the pre-clinical data on NXY-059 warrant its clinical development? What clinical-trial methodological issues were important? What general lessons for the future can be learned?
3. **Jun Chen:** Are any the molecular mediators of ischemic neuroprotection actually suitable for translation to human clinical trials? If so, which strategies appear the most promising? What is the status of peroxisome proliferator-activated receptor-gamma agonists? What translational difficulties would be anticipated?
4. **Giora Feuerstein:** Mechanistically based choice of neuroprotectants based on knowledge of their molecular targets – does this approach hold promise for actually identifying agents suitable for translation to the clinic? What are the current pharmaceutical-industry impediments to development of neuroprotectants?
5. **Thomas Hemmen:** Hypothermia – what obstacles remain for its successful translation to the clinic?
AND: Is reperfusion required for successful neuroprotection (in general)?

Moderated Discussion

1:00 PM – 1:45 PM LUNCH

1:45 PM – 3:15 PM

• **REHABILITATION - Moderators: Steven Cramer, Randy Nudo**

1. **Rajiv Ratan:** Novel pharmacological strategies for stroke rehabilitation
2. **Larry Goldstein:** Amphetamine Trials and Tribulations
3. **Theresa Jones:** Synaptic plasticity and motor rehabilitation after cortical damage
4. **Thomas Kent:** What is the evidence for use dependent learning after stroke?
5. **Alexander Dromerick:** Dosing of rehabilitation therapies

Moderated Discussion

3:30 PM – 5:00 PM

• **STEM CELL THERAPY - Moderators: Sean Savitz, Alison Willing**

1. **Sean Savitz:** Overall intro and where field stands
2. **Michael Chopp:** What are "the real" mechanisms of cell therapy?
3. **Cesar Borlongan:** Remaining Issues to Address Before Embarking on Clinical Trials
4. **Larry Wechsler:** Clinical Trials on Stroke Therapy. Which patients, which cells.
5. **Alison Willing:** How do our experimental models influence for better or worse our progress in the development of cell therapy for stroke?

Moderated Discussion: Richard Traytsman

5:00 PM Closing Remarks, James C. Grotta

7:30 PM Dinner at the Armadillo Palace